Enhancement of [3H]glutamate binding by N-methyl-D-aspartic acid in rat adrenal

Glutamate signaling in peripheral tissues

The hypothesis that l-glutamate (Glu) is an excitatory amino acid neurotransmitter in the mammalian central nervous system is now gaining more support after the successful cloning of a number of genes coding for the signaling machinery required for this neurocrine at synapses in the brain. These include Glu receptors (signal detection), Glu transporters (signal termination) and vesicular Glu transporters (signal output through exocytotic release). Relatively little attention has been paid to the functional expression of these molecules required for Glu signaling in peripheral neuronal and non-neuronal tissues; however, recent molecular biological analyses show a novel function for Glu as an extracellular signal mediator in the autocrine and/or paracrine system. Emerging evidence suggests that Glu could play a dual role in mechanisms underlying the maintenance of cellular homeostasis - as an excitatory neurotransmitter in the central neurocrine system and an extracellular signal mediator in peripheral autocrine and/or paracrine tissues. In this review, the possible Glu signaling methods are outlined in specific peripheral tissues including bone, testis, pancreas, and the adrenal, pituitary and pineal glands.

Epithelium-dependent effect of L-glutamate on airways: involvement of prostaglandins

We investigated the effect of the excitatory amino acid (EAA) receptor agonists L-glutamate, N-methyl-D-aspartate (NMDA), (RS)-a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) and kainic acid on KCl-induced contractions of rabbit tracheal smooth muscle, as well as the role of epithelium and endogenously produced nitric oxide and prostaglandins on these responses. L-Glutamate decreased KCI-induced contractions up to 30%. This effect was attenuated by epithelium removal, tetrodotoxin, methylene blue and indomethacin but not by NG-nitro-L-arginine methyl ester. While NMDA, AMPA and kainic acid had no effect, the combination of NMDA + kainic acid decreased KCI-induced contractions. These results suggest that, in rabbit trachea, L-glutamate has, at least in part, an epithelium-dependent effect mediated via prostaglandin formation and that the EAA receptors involved are non-classical.

Expression of a Functional N-Methyl-d-Aspartate–Type Glutamate Receptor by Bone Marrow Megakaryocytes

Better understanding of hemostasis will be possible by the identification of new lineage-specific stimuli that regulate platelet formation. We describe a novel functional megakaryocyte receptor that belongs to a family of ionotropic glutamate receptors of theN-methyl-d-aspartate (NMDA) subtype responsible for synaptic neurotransmission in the central nervous system (CNS). Northern blotting and reverse-transcriptase polymerase chain reaction (RT-PCR) studies identified expression of NMDAR1 and NMDAR2D type subunit mRNA in rat marrow, human megakaryocytes, and MEG-01 clonal megakaryoblastic cells. Immunohistochemistry and in vivo autoradiographic binding of the NMDA receptor-specific antagonist MK-801 confirmed that megakaryocytes expressed open channel-forming NMDA receptors in vivo. Western blots indicated that megakaryocyte NMDAR1 was either unglycosylated or only glycosylated to low levels, and of identical size to CNS-type NMDAR1 after deglycosylation with endoglycosidase F/peptide-N-glycosidase F. In functional studies, we demonstrated that NMDA receptor activity was necessary for phorbol myristate acetate (PMA)-induced differentiation of megakaryoblastic cells; NMDA receptor blockade by specific antagonists significantly inhibited PMA-mediated increases in cell size, CD41 expression, and adhesion of MEG-01 cells. These results provide evidence for a novel pathway by which megakaryocytopoiesis and platelet production may be regulated.

Expression of a Functional N-Methyl-d-Aspartate–Type Glutamate Receptor by Bone Marrow Megakaryocytes

Better understanding of hemostasis will be possible by the identification of new lineage-specific stimuli that regulate platelet formation. We describe a novel functional megakaryocyte receptor that belongs to a family of ionotropic glutamate receptors of theN-methyl-d-aspartate (NMDA) subtype responsible for synaptic neurotransmission in the central nervous system (CNS). Northern blotting and reverse-transcriptase polymerase chain reaction (RT-PCR) studies identified expression of NMDAR1 and NMDAR2D type subunit mRNA in rat marrow, human megakaryocytes, and MEG-01 clonal megakaryoblastic cells. Immunohistochemistry and in vivo autoradiographic binding of the NMDA receptor-specific antagonist MK-801 confirmed that megakaryocytes expressed open channel-forming NMDA receptors in vivo. Western blots indicated that megakaryocyte NMDAR1 was either unglycosylated or only glycosylated to low levels, and of identical size to CNS-type NMDAR1 after deglycosylation with endoglycosidase F/peptide-N-glycosidase F. In functional studies, we demonstrated that NMDA receptor activity was necessary for phorbol myristate acetate (PMA)-induced differentiation of megakaryoblastic cells; NMDA receptor blockade by specific antagonists significantly inhibited PMA-mediated increases in cell size, CD41 expression, and adhesion of MEG-01 cells. These results provide evidence for a novel pathway by which megakaryocytopoiesis and platelet production may be regulated.

Evidence for a novel glutamate-mediated signaling pathway in keratinocytes

Phenotypic alterations in keratinocyte behavior are essential for maintaining epidermal integrity during growth and wound repair and rely on co-ordinated cell signaling events. Numerous growth factors and cytokines have been shown to be instrumental in guiding such changes in keratinocyte activity; here we provide evidence which proposes a novel epidermal signaling pathway mediated by the excitatory amino acid glutamate. Glutamate is the major excitatory neurotransmitter at synaptic junctions within the central nervous system; however, we have identified expression in vivo of several regulatory molecules associated with glutamate signaling in keratinocytes. In resting rat skin epidermis, different classes of glutamate receptors, transporters, and a recently described clustering protein were shown to display distinct distribution patterns, supportive of a multifunctional cellular communication pathway. Immunoreactive N-methyl-D-aspartate-type, alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate-type, and metabotropic-type glutamate receptors were colocalized with the specific glutamate transporter EAAC1 in basal layer keratinocytes, and GLT-1, a related transporter, was expressed suprabasally. In full-thickness rat skin wounds, marked modifications in the distribution of N-methyl-D-aspartate receptors and EAAC1 were observed during re-epithelialization, and alterations in N-methyl-D-aspartate receptor expression accompanied embryonic epidermal development, implicating glutamate signaling in these important biologic events. Furthermore, we provide evidence that these receptors are functional in vitro. These data provide strong evidence to support a role for glutamate in the control of epidermal renewal, and therefore suggest potentially novel therapeutic targets for the treatment of skin disease and enhancement of wound healing.

Effect of glutamate receptor agonists on catecholamine secretion in bovine chromaffin cells

In this study, the effects of glutamate and glutamate receptor agonists in cultured chromaffin cells from bovine adrenal medulla were investigated. It was found that glutamate increases basal catecholamine (CA) secretion in a dose-dependent manner. This effect is mimicked by specific agonists of the four known glutamate receptors N-methyl-D-aspartate (NMDA), quisqualate/(RS)-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), kainate (KA), and trans-(+)-1-amino-1,3-cyclopentane dicarboxylic acid (t-ACPD), which increased both basal and nicotine-evoked CA secretion. The NMDA receptor antagonist 2-amino-5-phosphonopentanoic acid, 6-cyano-7-nitroquinoxaline-2,3-dione, an antagonist of KA and AMPA receptors, and L-(+)-2-amino-3-phosphonopropionic acid, an antagonist of the t-ACPD receptor, inhibited the stimulatory effect of related glutamate agonists. Hexamethonium, an antagonist of the nicotinic receptor, failed to influence glutamate agonists except for a 15% inhibition of KA. The increase in CA secretion produced by a 100 microM concentration of glutamate agonists was about 20-60% of that obtained with 10 microM of nicotine, an agonist of the physiological stimulatory cholinergic receptor. The increase in CA secretion produced by glutamate was accompanied by both an increase in bisoxonol fluorescence, suggesting membrane depolarization, and by an increase in intracellular Ca2+ concentrations. Results obtained with image analysis on single cells indicated that the percentage of cells which respond to the stimulation of 50 microM of glutamate is 42%. From these results, we conclude that glutamate, through its four known glutamate receptors, can increase both basal and nicotine-evoked CA secretion in chromaffin cells by a process which involves membrane depolarization and an increase in intracellular calcium levels.

Biochemical, autoradiographic and functional studies on a unique glutamate binding site in adrenal gland

L-Glutamate is known to function as a major excitatory neurotransmitter in the mammalian central nervous system, and recent reports suggest the existence of receptors for glutamate in several peripheral tissues. In the present study, the characteristics of the binding of [3H]L-glutamate to sections of bovine adrenal gland were studied, and the localisation of this binding was investigated in adrenal glands from cow, dog, rat and guinea pig. In addition, the effects of glutamate on catecholamine release from the perfused isolated bovine adrenal gland were investigated. Binding of [3H]L-glutamate to slide-mounted sections of bovine adrenal gland was of high affinity (Kd 0.4 microM), rapid, saturable, reversible, stereospecific and to a single population of sites. The pharmacological profile of this binding site appeared to be unique, and did not correspond to any of the central receptor subtypes for glutamate so far identified. In the adrenal gland of the cow, rat and guinea pig, the binding density of [3H]L-glutamate was higher in cortex than medulla, while this pattern was reversed in the canine adrenal gland. Glutamate had no effect on the basal secretion of noradrenaline or adrenaline from the perfused isolated bovine adrenal gland, and neither glutamate nor the glutamate receptor antagonist kynurenate altered the nicotine-stimulated release of these catecholamines. These results suggest the existence of a novel peripheral binding site for glutamate in the adrenal gland. The differential autoradiographic localisation of this binding site in the adrenal glands of the various species studied may reflect different functional properties of glutamate in these species, and suggests possible roles for glutamate in the modulation of adrenal function.

Excitatory amino acid receptors in the mammalian periphery

Aspartate and glutamate occur ubiquitously in free and chemically bound forms and have been considered primarily as substances of metabolic relevance. This focus has changed with the more recent discovery of their specific role as excitatory synaptic transmitters in the mammalian CNS. Enthusiasm for this concept has overshadowed the possibility that glutamate and aspartate may also have specific, receptor-mediated functions in the periphery. In this review, Sándor Erdö summarizes the current knowledge of excitatory amino acid (EAA) receptors outside the CNS, through which EAAs may modulate various functions in peripheral organs and tissues.

Neurochemical aspects of the N-methyl-D-aspartate receptor complex

The N-methyl-D-aspartic acid (NMDA)-sensitive subclass of brain excitatory amino acid receptors is supposed to be a receptor-ionophore complex consisting of at least 3 different major domains including an NMDA recognition site, glycine (Gly) recognition site and ion channel site. Biochemical labeling of the NMDA domain using [3H]L-glutamic acid (Glu) as a radioactive ligand often meets with several critical methodological pitfalls and artifacts that cause a serious misinterpretation of the results. Treatment of brain synaptic membranes with a low concentration of Triton X-100 induces a marked disclosure of [3H]Glu binding sensitive to displacement by NMDA with a concomitant removal of other several membranous constituents with relatively high affinity for the neuroactive amino acid. The NMDA site is also radiolabeled by the competitive antagonist (+/-)-3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid that reveals possible heterogeneity of the site. The Gly domain is sensitive to D-serine and D-alanine but insensitive to strychnine, and this domain seems to be absolutely required for an opening of the NMDA channels by agonists. The ionophore domain is radiolabeled by a non-competitive type of NMDA antagonist that is only able to bind to the open but not closed channels. The binding of these allosteric antagonists is markedly potentiated by NMDA agonists in a manner sensitive to antagonism by isosteric antagonists in brain synaptic membranes and additionally enhanced by further inclusion of Gly agonists through the Gly domain. Furthermore, physiological and biochemical responses mediated by the NMDA receptor complex are invariably potentiated by several endogenous polyamines, suggesting a novel polyamine site within the complex. At any rate, activation of the NMDA receptor complex results in a marked influx of Ca2+ as well as Na+ ions, which subsequently induces numerous intracellular metabolic alterations that could be associated with neuronal plasticity or excitotoxicity. Therefore, any isosteric and allosteric antagonists would be of great benefit for the therapy and treatment of neurodegenerative disorders with a risk of impairing the acquisition and formation process of memories.

Labeling of NMDA receptor channels by [3H]MK-801 in brain synaptic membranes treated with Triton X-100

Binding activity of [3H](+)-5-methyl-10, 11-dihydro-5H-dibenzo [a,d] cyclohepten-5, 10-imine maleate (MK-801) was examined by using rat brain synaptic membranes treated with Triton X-100. This compound is known as a non-competitive antagonist for one subclass of the central excitatory amino acid receptors, N-methyl-D-aspartic acid (NMDA)-sensitive receptors. Triton treatment completely abolished the temperature-dependent portion of the binding activity, with a concomitant reduction of membranous protein content. Addition of L-glutamic acid (Glu), however, markedly potentiated the activity at concentrations higher than 10 nM in a temperature-dependent manner. Similarly significant potentiation was induced by structurally related amino acids as well as agonists for the NMDA-sensitive receptors, but not by agonists for the other subclasses. The rank order of this stimulatory potency was well consistent with that of the displacing activity of these Glu analogues on NMDA-sensitive [3H]Glu binding. Competitive NMDA antagonists, such as (+/-)-3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid and D-2-amino-5-phosphonovaleric acid, were all effective in preventing the potentiation of [3H]MK-801 binding activity by L-Glu. The latter Glu-dependent activity was additionally enhanced by glycine and its analogues at concentrations above 10 nM in a temperature- and Glu-dependent fashion. Additional enhancement by glycine was also antagonized by competitive NMDA antagonists, but not by a classical glycine antagonist strychnine. These results suggest that Triton X-100-treated membranes are suitable for the study of the interaction of the non-competitive antagonists with NMDA receptor channels, and may be superior to non-detergent-treated membranes in terms of freedom from the confounding effects of endogenous amino acids.

N-methyl-D-aspartate-sensitive [3H]glutamate binding sites in brain synaptic membranes treated with Triton X-100

Specific binding activity of radiolabeled L-glutamic acid, a putative central excitatory neutrotransmitter, was drastically increased with increasing concentrations of Triton X-100 used for pretreatment of rat brain synaptic membranes. The binding in these Triton-treated membranes was a protein dependent, inversely temperature-dependent, stereospecific, structure-selective and saturable process with a high affinity for the amino acid. The binding activity was invariably inhibited by agonists and antagonists for the N-methyl-D-aspartic acid (NMDA)-sensitive subclass, but not by agonists for the other subclasses of excitatory amino acid neurotransmitter receptors in the brain. Scatchard analysis revealed that the binding sites consisted of a single component with a Kd of 24.4 +/- 2.5 nM and a Bmax of 0.94 +/- 0.09 pmol/mg protein. Some endogenous tryptophan metabolites such as kynurenic acid and quinolinic acid also inhibited the binding. These results suggest that synaptic membranes may indeed contain the NMDA-sensitive receptors which are disclosed by Triton X-100 treatment.

Solubilization of stereospecific and quisqualate-sensitive activity of [3H]glutamate binding in the pituitary of the rat

Binding activity of a putative central excitatory neurotransmitter, L-glutamic acid, was solubilized from the pituitary glands of the rat by treatment of the membranous homogenates with a nonionic detergent, Nonidet P-40. The binding activity of [3H]glutamic acid increased linearly with increasing concentrations of the solubilized proteins, up to 15 micrograms. The binding activity reached an equilibrium within 10 min at 2 degrees C, while the time required to attain equilibrium at 30 degrees C was 60 min. Addition of an excess of nonradioactive glutamic acid rapidly decreased the activity detected at 30 degrees C, to the nonspecific binding level. Scatchard analysis of these data revealed that the solubilized binding activity consisted of a single component with a Kd of 0.34 microM and a Bmax of 53.6 pmol/mg protein. L-Glutamic but not D-glutamic acid inhibited the binding activity in a concentration-dependent manner, at the concentration range greater than 10(-8) M. An agonist for a certain subclass of the central glutamate receptors, quisqualic acid, significantly inhibited the solubilized activity, whereas the other two agonists, such as N-methyl-D-aspartic acid and kainic acid, had no significant effect. Reduction of the incubation temperature from 30 degrees C to 2 degrees C resulted in a drastic attenuation of the binding activity due to a decrement in the number of apparent binding sites. These results suggest that the binding activity of [3H]glutamic acid in the pituitary may be derived from a quisqualate-sensitive membranous constituent with a stereospecific high affinity for the central neurotransmitter.

Stimulation of peripheral cholinergic nerves by glutamate indicates a new peripheral glutamate receptor

The bronchial smooth muscle of the rat was examined for contractile responses to excitatory amino acids. The nerve-mediated contraction induced by electrical field stimulation was enhanced by exogenous L-glutamate (L-Glu). The apparent affinity (ED50) of L-Glu was 3.5 +/- 0.1 mM. Both tetrodotoxin and hemicholinium-3 completely abolished the electrical field-induced contraction and therefore the potentiation by L-Glu, which indicates that L-Glu has a prejunctional effect. Concentrations of L-Glu higher than 22 mM inhibited the electrical field-induced contractions and enhanced the tonus of the smooth muscle by postjunctional stimulation. The ED50 of exogenous ACh was not altered by L-Glu. High concentrations (62 mM) of L-Glu increased the intrinsic activity (alpha) of ACh, indicating a postjunctional potentiation of ACh-induced contractions. L-Glu did not inhibit the activity of acetylcholinesterase, therefore the postjunctional potentiation was not due to ACh accumulation. Inhibition of the electrical field-induced contraction was seen with high concentrations of D-Glu, L-aspartate (L-Asp), L-alpha-amino adipate and ibotenate. Neither glutamate diethyl ester nor 2-amino-5-phosphonovalerate had any inhibitory effects on the L-Glu- and L-Asp-induced alterations of the electrical field-stimulated contraction or on the L-Glu-enhanced tonus of the bronchial smooth muscle. Kainate, N-methyl-D-aspartate, quisqualate and N-acetyl-aspartyl-glutamate had only minor transient potentiating effects on the electrical field-induced contraction. The results provide evidence for a L-Glu receptor in rat bronchi that has a different specificity for glutamate agonists and antagonists than the L-Glu receptor described in the CNS. The receptor seems to be located prejunctionally and enhances nerve-mediated responses and thereby stimulates the bronchial smooth muscle to contract. The possible involvement of this type of receptor in the 'Chinese restaurant syndrome' is discussed.

Selective potentiation by L-cysteine of apparent binding activity of [3H]glutathione in synaptic membranes of rat brain

Significant apparent binding activity of [3H]glutathione was detected in synaptic membranous preparations of the rat brain. In vitro addition of sucrose (50-1000 mM) and Triton X-100 (0.02-0.1%) significantly diminished the apparent binding activity, whereas pretreatment of the membranes with Triton X-100 (0.01-0.4%) did not affect the activity. A slight but statistically significant reduction of the apparent binding activity was induced by the in vitro addition (1 mM) of two constituent amino acids, L-glutamic acid and glycine. In contrast, another constituent amino acid, L-cysteine, potently enhanced the binding activity at a concentration higher than 0.1 mM. No prominent alteration of the activity occurred following the inclusion of structurally-related amino acids, dithiothreitol, dithioerythritol and numerous other amino acids. Scatchard analysis revealed that the apparent binding consisted of two independent separate components with Kd values of 0.76 and 11.0 microM, and Bmax values of 4.00 and 27.0 pmol/mg protein respectively. In vitro addition of 1 mM L-cysteine resulted in a single component with a Kd of 8.5 microM and a Bmax of 105 pmol/mg protein. Pretreatment of the membranes with 1 mM L-cysteine potentiated the apparent binding, with a further addition of L-cysteine having no effect. The retina had the highest activity followed by the hypothalamus, striatum, spinal cord, midbrain, hippocampus, medulla-pons, cerebellum and cerebral cortex, which occurred independently of the incubation temperature. In peripheral organs examined, the pituitary possessed higher activity than the retina, with progressively lower activities in the adrenal, liver, spleen, skeletal muscle and heart. No significant activity was detected in the kidney. Addition of 1 mM L-cysteine significantly potentiated the activities at 30 degrees, but not at 2 degrees, in the hippocampus and cerebral cortex without affecting those in other central structures. In contrast, a profound inhibition of the activity was induced by the addition of L-cysteine in the pituitary, adrenal, intestinal mucosa, skeletal muscle and retina independently of the temperature. These results suggest that L-cysteine may selectively potentiate the apparent binding activity of [3H]glutathione in particular regions of the brain, while eliminating that in the peripheral excitable tissues.

Solubilization of quisqualate-sensitive [3H]glutamate binding activity from rat retina

Binding activity of a putative central neurotransmitter, L-glutamic acid, was examined in the supernatant preparations solubilized from rat retinal membranes by Nonidet P-40. [3H]Glutamate binding activity increased linearly with increasing concentrations of the solubilized proteins up to 15 micrograms. The binding activity reached an equilibrium within 10 min at 2 degrees C, while increasing with incubation time up to 60 min at 30 degrees C. Addition of an excess of nonradioactive glutamate rapidly decreased the activity at 30 degrees C. Scatchard analysis revealed that the solubilized retinal binding activity consisted of a single component with a KD of 0.25 microM and a Bmax of 57.4 pmol/mg protein. The solubilized binding activity exhibited a stereospecificity and a structure selectivity to L-glutamate, and was abolished by quisqualate, L-glutamate diethyl ester, and DL-2-amino-3-phosphonopropionate. None of the other agonists and antagonists for the central excitatory amino acid receptors affected the binding activity. Reduction of incubation temperature from 30 degrees C to 2 degrees C resulted in a drastic attenuation of the binding activity due to decrement of the number of the apparent binding sites. Cation-exchange column chromatography revealed that unidentified radioactive material was in fact formed during the incubation of [3H]glutamate with the retinal preparations at 30 degrees C. These results suggest that retinal [3H]glutamate binding activity may be derived at least in part from the quisqualate-sensitive membranous enzyme with a stereospecific and structure-selective high affinity for the central neurotransmitter.

Temperature-dependent and -independent apparent binding activities of [3H]glutathione in brain synaptic membranes

An apparent binding activity of [3H]glutathione was examined by using synaptic membrane preparations of the rat brain. The activity was found to be more than two times as high at 30 degrees C as that found at 2 degrees C. At 2 degrees C, the apparent binding sites consisted of a single component with a Kd of 0.77 microM and a Bmax of 5.60 pmol/mg protein. In contrast, two independent separate sites with Kds of 0.56 and 12.6 microM and Bmaxs of 2.50 and 28.5 pmol/mg protein were observed at 30 degrees C. In vitro addition of Triton X-100 significantly inhibited the apparent binding activities detected at both temperatures, whereas pretreatment of the membranes with the detergent did not significantly affect both binding activities. Among 3 constituent amino acids of glutathione, L-cysteine induced a selective and irreversible potentiation of the apparent activities, which occurred independently of the incubation temperature. Scatchard analysis revealed that L-cysteine drastically increased the number of the low affinity sites without significantly altering their affinity. Apparent binding activities determined at both incubation temperatures were unevenly distributed in the central and peripheral structures. Distribution profile of the temperature-dependent activities was found to be closely related to that of the basal binding activity of [3H]L-glutamic acid, a putative central excitatory neurotransmitter. These results suggest that brain synaptic membranes may indeed contain specific binding sites of [3H]glutathione which have an interaction with the glutamate binding sites. Possible presence of two distinctly different apparent binding sites of [3H]glutathione, such as temperature-independent high affinity sites and temperature-dependent low affinity sites, is also suggested.